Attentional Control Training in Older Adults: Efficacy, Transfer and Brain Substrates
NCT03532113, Not applicable, Completed, Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Attentional Control Training in Older Adults: Efficacy, Transfer and Brain Substrates | ClinicalTrials.gov |
| NCT number | NCT03532113 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 90 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal | ClinicalTrials.gov |
| Conditions | Inhibition (Psychology), Updating, General Knowledge, No Training | ClinicalTrials.gov |
| Interventions | Updating, Inhibition, General knowledge | ClinicalTrials.gov |
| First posted | 2018-05-22 | ClinicalTrials.gov |
| Last updated | 2020-01-23 | ClinicalTrials.gov |
Registered outcomes 17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Changes on the updating composite measure (Proximal outcome). | within the 2 weeks before intervention starts; 3rd week after intervention starts (after the 6th training session); 6th week (after the 12th training session) | An updating composite score will be computed by averaging z-scores from the Keep track task and the Running span task. | ClinicalTrials.gov |
| Primary | Changes on the inhibition composite measure (Proximal outcome). | within the 2 weeks before intervention starts; 3rd week after intervention starts (after the 6th training session); 6th week (after the 12th training session) | An inhibition composite score will be computed by averaging z-scores from the Anti-saccade and the Victoria Stroop Test. | ClinicalTrials.gov |
| Secondary | Transfer to complex working memory measure: the Alpha-span task (Distal outcome). | within the 2 weeks before intervention starts; 1st week after intervention starts (after the 3rd training session); 3rd week (after the 6th training session); 4th week (after the 9th training session); 6th week (after the 12th training session). | Accuracy on the alphabetic portion of the Alpha-span task | ClinicalTrials.gov |
| Secondary | Transfer to complex working memory measure: the Reading span task (Distal outcome). | within the 2 weeks before intervention starts; 1st week after intervention starts (after the 3rd training session); 3rd week (after the 6th training session); 4th week (after the 9th training session); 6th week (after the 12th training session). | Accuracy on the Reading span task. | ClinicalTrials.gov |
| Secondary | Transfer to complex working memory measure: the virtual car ride task (Distal outcome). | within the 2 weeks before intervention starts; 1st week after intervention starts (after the 3rd training session); 3rd week (after the 6th training session); 4th week (after the 9th training session); 6th week (after the 12th training session). | Average z-score computed with the verbal and visual (accuracy and RT) components of the divided attention virtual reality task. | ClinicalTrials.gov |
| Secondary | Brain structure: Regional gray matter volumes in Prefrontal and lateral temporal cortices, Basal ganglia and Hippocampi. | within the 2 weeks before intervention starts; 3rd week after intervention starts (after the 6th training session); 6th week (after the 12th training session) | A T1-weighted 3D-MPRAGE sequence (TR/TE 2300/2.98ms, Fa 9°, FOV = 256\*256, matrix 256\*256, voxels 1mm³, 192 slices) will be used to measure regional gray matter volume. | ClinicalTrials.gov |
| Secondary | Brain structure: Cortical thickness in Prefrontal regions and lateral temporal cortices. | within the 2 weeks before intervention starts; 3rd week after intervention starts (after the 6th training session); 6th week (after the 12th training session) | A T1-weighted 3D-MPRAGE sequence (TR/TE 2300/2.98ms, Fa 9°, FOV = 256\*256, matrix 256\*256, voxels 1mm³, 192 slices) will be used to measure cortical thickness (FreeSurfer 5.3). | ClinicalTrials.gov |
| Secondary | Brain function: Updating related activation. | within the 2 weeks before intervention starts; 3rd week after intervention starts (after the 6th training session); 6th week (after the 12th training session) | Functional activations. Simultaneous multislice (accelerator factor = 6), echo polar (EPI) imaging: TR/TE 785/30 ms, Fa 54°, FOV 192\*192, matrix 64\*64, voxels 3 mm³, 39 slices) will be measured in association with a N-back task. | ClinicalTrials.gov |
| Secondary | Brain function: Inhibition related activation. | within the 2 weeks before intervention starts; 3rd week after intervention starts (after the 6th training session); 6th week (after the 12th training session) | Functional activations. Simultaneous multislice (accelerator factor = 6), echo polar (EPI) imaging: TR/TE 785/30 ms, Fa 54°, FOV 192\*192, matrix 64\*64, voxels 3 mm³, 39 slices) will be measured in association with a counting stroop. | ClinicalTrials.gov |
| Other | Effect of moderators: Polymorphisms. | 3rd week after intervention starts (after the 6th training session) | Presence/absence of polymorphisms : Brain-derived neurotrophic factor (BDNF), Catechol-O-Methyltransferase (COMT) and Apolipoprotein (APOE)-ε4 taken from a salivary sample collected using an Oragene OG-500 collection kit. | ClinicalTrials.gov |
| Other | Effect of moderators: Cognitive reserve proxies. | within the 2 weeks before intervention starts | Scores on the reserve-proxy questionnaire (from Rami L, Valls-Pedret C, Bartres-Faz D, et al. 2011). | ClinicalTrials.gov |
| Other | Effect of moderators: Intracranial volume. | within the 2 weeks before intervention starts | Overall intracranial volume taken from MRI scan with a T1-weighted 3D-MPRAGE sequence (TR/TE 2300/2.98ms, Fa 9°, FOV = 256\*256, matrix 256\*256, voxels 1mm³, 192 slices). | ClinicalTrials.gov |
| Other | Effect of moderators: White Matter Lesions (WML). | within the 2 weeks before intervention starts | The WML will be quantified in mm3 (De Carli et al. 2005) from the FLAIR sequence (TR/TE 9000/120 ms, Fa 90°, FOV 240\*240, matrix 256\*256, voxels 0.9\*0.9\*3 mm, 48 slices). | ClinicalTrials.gov |
| Other | Effect of moderators: Regional gray matter volumes in Prefrontal and lateral temporal cortices, Basal ganglia and Hippocampi. | within the 2 weeks before intervention starts | A T1-weighted 3D-MPRAGE sequence (TR/TE 2300/2.98ms, Fa 9°, FOV = 256\*256, matrix 256\*256, voxels 1mm³, 192 slices) will be used to measure regional gray matter volume. | ClinicalTrials.gov |
| Other | Effect of moderators: Cortical thickness in Prefrontal regions and lateral temporal cortices. | within the 2 weeks before intervention starts | A T1-weighted 3D-MPRAGE sequence (TR/TE 2300/2.98ms, Fa 9°, FOV = 256\*256, matrix 256\*256, voxels 1mm³, 192 slices) will be used to measure cortical thickness (FreeSurfer 5.3). | ClinicalTrials.gov |
| Other | Effect of moderators: Task related activation in prefrontal and lateral temporal cortices, Basal ganglia and Hippocampi. | within the 2 weeks before intervention starts | Functional activations. Simultaneous multislice (accelerator factor = 6), echo polar (EPI) imaging: TR/TE 785/30 ms, Fa 54°, FOV 192\*192, matrix 64\*64, voxels 3 mm³, 39 slices) will be measured in association with a N-back task and a counting stroop. | ClinicalTrials.gov |
| Other | Effect of moderators: Sex. | within the 2 weeks before intervention starts | Male vs Female. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 3
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 7
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Antisaccade Task | Primary outcome | ConductCognition |
| Keep-Track Task | Primary outcome | ConductCognition |
| Running Span | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| 1-Back Task | Secondary outcome | ConductCognition |
| 2-Back Task | Secondary outcome | ConductCognition |
| Reading Span Task | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)